2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2282

“Doing Every-Day Life” with Primary Sjögren’s Syndrome: Factors Predicting Difficulties Performing Daily Activities and Taking on Life Roles
Abstract Number: 1087

“It Was Just My Right Pace”: A Qualitative Study Exploring Yoga Practice in Adults with Rheumatoid Arthritis
Abstract Number: 2338

“It Was like No One Is Listening to Me”�: A Qualitative Study of the Lived Experiences of Patients with Rheumatoid Arthritis in the Setting of Patient-Physician Discordance in Assessments of Disease Activity
Abstract Number: 2217

#Rheumjc: Development, Implementation and Analysis of an International Twitter-Based Rheumatology Journal Club
Abstract Number: 2555

14-3-3η As a Novel RA Drug Target: Anti-14-3-3η Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice
Abstract Number: 2605

14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA
Abstract Number: 1319

18F-Fluorodeoxyglucose Positron Emission Computer Tomography and Ultrasonography for Assessing Remission in Patients with Rheumatoid Arthritis
Abstract Number: 2957

25-Hydroxyvitamin D3 Deficiency Independently Predicts Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Results from a Controlled Study
Abstract Number: 2706

3D Location of Erosions in an Early Rheumatoid Arthritis Population: An MRI Study Using Statistical Shape Models with Implications for Pathogenesis
Abstract Number: 179

3D Ultrasound Doppler Findings in Finger Tendon Sheaths of Healthy Controls
Abstract Number: 178

3D Ultrasound Doppler Findings in Wrist Tendon Sheaths of Healthy Controls
Abstract Number: 1681

4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL
Abstract Number: 1420

6-Month Change in Pain and Function By Pre-Surgery Pain and Function Among Patients Selected for Total Knee Replacement in the United States
Abstract Number: 1474

8-Year Follow-up Study: Differences Between HLA-B27 Positive and Negative Children with Juvenile Idiopathic Arthritis in Finland
Abstract Number: 2344

A 3-Year Follow-up Study of Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant, or Unresponsive to Nonsteroidal Anti-Inflammatory Drugs and/or Colchicine

1
2
3
…
218
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].